GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures

Phase 2

Withdrawn

Conditions: Epilepsy

First Posted Date: 2007-12-05

Last Posted Date: 2013-04-04

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT00567424

Locations: 🇺🇸
GSK Clinical Trials Call Center, Seattle, Washington, United States

A Clinical Evaluation Of BW430C (Lamotrigine) In Bipolar I Disorder- Long-term Extension Of Study SCA104779 (NCT00550407) -

Phase 3

Completed

Conditions: Bipolar Disorder

Interventions: Drug: BW430C (lamotrigine)

First Posted Date: 2007-11-30

Last Posted Date: 2017-04-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 92

Registration Number: NCT00566020

Locations: 🇯🇵
GSK Investigational Site, Yamagata, Japan

To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]SB-681323 in Healthy Adult Males

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: A single 10 milligram (50 microcurie) oral dose of [14C]SB-681323

First Posted Date: 2007-11-28

Last Posted Date: 2017-08-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 4

Registration Number: NCT00564746

Locations: 🇬🇧
GSK Investigational Site, Tranent, West Lothian, United Kingdom

A Study to Evaluate Safety, Side Effects, Muscle Activity and Speed of Gastric Emptying of GSK962040

Phase 1

Completed

Conditions: Gastroparesis

Interventions: Drug: GSK962040
Drug: Placebo

First Posted Date: 2007-11-22

Last Posted Date: 2017-08-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 48

Registration Number: NCT00562848

Locations: 🇧🇪
GSK Investigational Site, Leuven, Belgium

Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors

Phase 2

Completed

Conditions: Tumor
Epithelial Ovarian Cancer
Cervix Diseases
Primary Peritoneal Carcinoma
Cancer
Uterine Disease
Neoplasms, Ovarian

Interventions: Drug: pazopanib (GW786034)
Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2007-11-21

Last Posted Date: 2012-03-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 12

Registration Number: NCT00561795

Locations: 🇩🇪
GSK Investigational Site, Essen, Nordrhein-westfalen, Germany

A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2

First Posted Date: 2007-11-16

Last Posted Date: 2012-06-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 36

Registration Number: NCT00559884

Locations: 🇺🇸
GSK Investigational Site, Columbus, Ohio, United States

Patient Tolerability Study of GSK163090

Phase 1

Completed

Conditions: Depressive Disorder, Major
Major Depressive Disorder (MDD)

First Posted Date: 2007-11-16

Last Posted Date: 2012-03-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 20

Registration Number: NCT00559299

Locations: 🇺🇸
GSK Investigational Site, Wichita, Kansas, United States

Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD)

Phase 2

Terminated

Conditions: Post-Traumatic Stress Disorder
Stress Disorders, Post-Traumatic

Interventions: Other: placebo
Drug: paroxetine

First Posted Date: 2007-11-14

Last Posted Date: 2020-11-30

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 5

Registration Number: NCT00557622

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer

Phase 2

Completed

Conditions: Neoplasms, Breast

Interventions: Drug: lapatinib
Drug: Pazopanib

First Posted Date: 2007-11-14

Last Posted Date: 2013-02-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 163

Registration Number: NCT00558103

Locations: 🇬🇧
GSK Investigational Site, Sutton, United Kingdom

ARTS - AVODART After Radical Therapy For Prostate Cancer Study

Phase 2

Completed

Conditions: Neoplasms, Prostate
Prostate Cancer After a Radical Treatment

Interventions: Other: placebo
Drug: Avodart

First Posted Date: 2007-11-14

Last Posted Date: 2012-03-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 294

Registration Number: NCT00558363

Locations: 🇬🇧
GSK Investigational Site, High Heaton, Newcastle Upon Tyne, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy